Sirs,
Frontotemporal dementia (FTD) is the second mostcommon neurodegenerative dementia after Alzheimer's disease (AD), with a frequency of 12%-20% among patients with an onset of dementia below 65 years. Causal mutations leading to FTD were identified in the microtubule-associated protein tau (MAPT) gene located at 17q21. In several autosomal dominant tau-negative FTD families, however, mutations in MAPT could not be identified, despite conclusive linkage to 17q21 [1, 2, 3] . We hypothesized that this subtype of FTD could result from mutations in the gene encoding presenilin (PS) homologue 2 (PSH2), located 50 kb upstream of MAPT. PSH2 is one of five members of a novel family of proteins showing membrane topology and putative catalytic domains similar to PS [4] . Because mutations in presenilins 1 and 2 are responsible for early onset AD [5] (http://molgen-www.uia.ac.be/ADMutations), mutations in PSHs might also lead to neurodegeneration. Previously, mutation analysis of PSH2 in probands of four taunegative FTD families failed to identify PSH2 mutations [4] , but these families were not informative for linkage to 17q21.
We described a four-generation family, 1083, ascertained in a population-based study in the Netherlands [6] , which presented with a clinical phenotype similar to FTD and a mean onset age of 64.9 years (range 53-79 years) [2] . Autopsy demonstrated severe frontal atrophy and complete lack of tau neuropathology in the presence of ubiquitin-positive tau-negative inclusions. A genomewide scan identified conclusive linkage (multipoint LOD score=5.51) in a candidate region of 4.8 cM at 17q21 comprising MAPT. Extensive mutation analysis of MAPT coding and regulatory sequences failed to identify disease-related mutations [2] .
In this study, we performed mutation analysis of PSH2 by direct sequencing of three overlapping PCR amplicons of genomic DNA between positions g.6 and g.2195 in XM_091623.4, corresponding to the only coding exon of PSH2, and including 67 bp upstream and 68 bp downstream regulatory sequences. In total we identified 5 novel (Table 1 ) and 10 known single nucleotide polymorphisms (SNPs) (see electronic supplementary Fig. 1 ). Segregation analysis in the family indicated that only 1 novel SNP g.1698G>A was contained in the disease haplotype leading to a silent mutation at codon S542. We used a pyrosequencing assay to analyze 89 Dutch control individuals and identified 2 controls that were homozygous and 20 heterozygous for the A allele, resulting in a minor allele frequency of 13.5%. Segregation analysis also illustrated that 4 of the 5 novel SNPs were in linkage disequilibrium with the extended MAPT haplotypes H1/ H2, defined by polymorphic alleles in MAPT exons 1, 2, 3, 9, 11, and 13 [7] (see electronic supplementary Fig. 1 ).
These data confirmed that MAPT haplotype blocks extend to PSH2, as previously shown by Ponting et al. [4] .
In conclusion, we excluded by direct sequencing pathogenic mutations in PSH2 as a causative defect for 17q21-linked tau-negative FTD using mutation and segregation analysis in the most-informative family known to date. It is also unlikely that the single PSH2 coding exon or part of it is deleted, since all patients were heterozygous for the linked SNP g.1698G>A, and since in all three PCR amplicons heterozygote SNPs were identified in at least one patient. A gene duplication of PSH2 cannot be fully excluded by the methods we used in the mutation analysis. However, the apparent accumulation of non-synonymous SNPs within the PSH2 coding sequence is indicative of a non-functional processed pseudogene [4] (this study). Therefore, our data suggest that another defective gene at 17q21 should also be considered for this subtype of FTD. Since 64% of all FTD patients do not display tau pathology, and since the MAPT mutation frequency in familial FTD is less than 50%, the genetic defect leading to tau-negative dementia might be an important factor in the etiology of FTD. Its identification will likely contribute to our understanding of this important neurodegenerative dementia. a For g.1698G>A, allele frequencies were calculated in 190 unrelated control chromosomes, the others were calculated in the 3 patients and 1 control of family 1083 of whom 3 shared the same haplotype
